G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival
Megan Othus,Mikkael A. Sekeres,Sucha Nand,Guillermo Garcia-Manero,Frederick R. Appelbaum,Harry P. Erba,Elihu H. Estey,Elihu H. Estey +7 more
TL;DR: CR was significantly associated with prolonged survival among MDS pts treated with azactidine on S1117, and achievement of morphologic CR was associated with a 60% improvement in OS, on average, compared to that seen in pts who don't achieve a CR, regardless of whether pts were treated with 7+3 or AZA.
Journal ArticleDOI
Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
Naveen Pemmaraju,Hagop M. Kantarjian,Susan O'Brien,Gautam Borthakur,Farhad Ravandi,Srdan Verstovsek,Naval Daver,Guillermo Garcia-Manero,Courtney D. DiNardo,Jeffrey Skinner,Marina Konopleva,Sherry Pierce,Elias Jabbour,Jorge E. Cortes +13 more
TL;DR: The primary endpoint was achievement of major molecular response (MMR) at 12 months, and rapid CCyR occurs in nearly all pts, and MMR was achieved in 90% of pts with previously untreated CML-CP treated with front-line dasatinib.
Journal ArticleDOI
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Masamitsu Yanada,Xuelin Huang,Guillermo Garcia-Manero,Susan O'Brien,Farhad Ravandi,Gautam Borthakur,Stefan Faderl,Jean Pierre J. Issa,Hagop M. Kantarjian,Elihu H. Estey +9 more
TL;DR: Comparison of subsequent survival in patients with newly diagnosed AML or high-risk MDS according to whether, TT produced HI but not CR, or produced neither HI nor CR is compared.
Journal ArticleDOI
Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
Koji Sasaki,Hagop M. Kantarjian,Farhad Ravandi,Naval Daver,Tapan M. Kadia,Rita Khouri,Yesid Alvarado,Jan A. Burger,Deborah A. Thomas,Guillermo Garcia-Manero,Courtney D. DiNardo,Naveen Pemmaraju,Nicholas J. Short,Heather M Schroeder,Rebecca Garris,Prithviraj Bose,Nitin Jain,Kiran Naqvi,William G. Wierda,Srdan Verstovsek,Jorge E. Cortes,Marina Konopleva,Susan O'Brien,Elias Jabbour +23 more
TL;DR: Ofatumumab (HuMax-CD20) targets a membrane proximal small-loop epitope on the CD20 molecule and was found to be more potent than rituximab in promoting complement-dependent cytotoxicity in vitro and may be associated with better response rates, higher 3-year CRD and overall survival rates.
Journal ArticleDOI
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Koji Sasaki,Hagop M. Kantarjian,Kiyomi Morita,Nicholas J. Short,Marina Konopleva,Nitin Jain,Farhad Ravandi,Guillermo Garcia-Manero,Sa Wang,Joseph D. Khoury,Jeffrey L. Jorgensen,Richard E. Champlin,Issa F. Khouri,Partow Kebriaei,Heather M Schroeder,Maria Khouri,Rebecca Garris,Koichi Takahashi,Susan O'Brien,Elias Jabbour +19 more
TL;DR: In this paper, the authors compared the outcomes of 69 patients treated with hyper-CVAD + ofatumumab and 95 historical-control patients treating with hyperCVAD+Rituximab.